NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

Evaluation of 4-Hydroxyquinoline-3-Carboxamide Class of Compounds as Novel Inhibitors of Epstein-Barr Virus and Human Herpesvirus-8.

HOPKINS TA, HUANG A, OIEN NL, VAILLANCOURT VA, WATHEN MW; Interscience Conference on Antimicrobial Agents and Chemotherapy (41st : 2001 : Chicago, Ill.).

Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 2001 Dec 16-19; 41: abstract no. F-1668.

Pharmacia Corporation, Kalamazoo, MI

BACKGROUND: Broad screening of the Pharmacia compound collection has led to the discovery of a 4-hydroxyquinoline-3-carboxamide (4-HQ) class of antivirals with specificity towards herpesviruses. These novel non-nucleoside compounds demonstrate potent inhibition of human cytomegalovirus (HCMV), herpes simplex virus type 1 (HSV-1), and varicella zoster virus (VZV) polymerases, but do not inhibit human alpha, delta or gamma polymerases. METHODS: To determine if the activity of 4-HQ herpesvirus polymerase inhibitors extend to the gamma herpesviruses such as Epstein-Barr virus (EBV) and human herpesvirus-8 (HHV-8), we cloned their polymerases and requisite accessory binding proteins. Inhibition by the 4-HQs was evaluated in polymerase assays using in vitro transcribed/translated polymerases and accessory binding proteins. RESULTS: The 4-HQs potently inhibited the EBV and HHV-8 polymerases with IC[50] values typically ranging from 1-10 micro-M. These results were similar to the activity of 4-HQs against the HCMV and HSV-1 polymerases under equivalent assay conditions. In addition, these compounds potently inhibited EBV and HHV-8 replication in antiviral cell culture based assays. PNU-183792, one of our leading compounds, was 25x more potent than acyclovir at inhibiting EBV DNA replication. CONCLUSIONS: The 4-HQs represent a novel class of non-nucleoside antivirals with the potential for treating many of the diseases caused by herpesviruses including EBV and HHV-8.

Publication Types:
  • Meeting Abstracts
Keywords:
  • Acyclovir
  • Antiviral Agents
  • Cytomegalovirus
  • Ganciclovir
  • Herpesviridae
  • Herpesviridae Infections
  • Herpesvirus 1, Human
  • Herpesvirus 3, Human
  • Herpesvirus 4, Human
  • Herpesvirus 8, Human
  • Humans
  • Hydroxyquinolines
  • In Vitro
  • Nucleosides
  • PNU183792
  • Quinolines
  • Sarcoma, Kaposi
  • methods
Other ID:
  • GWAIDS0030333
UI: 102269970

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov